Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
HOTH Stock Price Chart Interactive Chart >
HOTH Price/Volume Stats
| Current price | $2.17 | 52-week high | $40.74 |
| Prev. close | $2.06 | 52-week low | $2.00 |
| Day low | $2.04 | Volume | 75,600 |
| Day high | $2.19 | Avg. volume | 905,228 |
| 50-day MA | $3.88 | Dividend yield | N/A |
| 200-day MA | $7.06 | Market Cap | 3.12M |
Hoth Therapeutics, Inc. (HOTH) Company Bio
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
Latest HOTH News From Around the Web
Below are the latest news stories about HOTH THERAPEUTICS INC that investors may wish to consider to help them evaluate HOTH as an investment opportunity.
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colo |
Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting ActivityHoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ("ShareIntel"), a patented compliance driven SAAS retained by public companies to track shareholder ownership and monitor critical broker-dealer and shareholder movement, to investigate and report on potential illegal naked short selling activities of Company stock (HOTH), among other potential trading violati |
Why Are Hoth Therapeutics Shares Moving Today?Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ. HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer's. Hoth reports that the longer treatment before the beginning of testing improves the performance of more |
Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZHoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ is a therapeutic i |
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast c |
HOTH Price Returns
| 1-mo | N/A |
| 3-mo | -34.44% |
| 6-mo | -76.09% |
| 1-year | -87.05% |
| 3-year | -96.79% |
| 5-year | N/A |
| YTD | -72.18% |
| 2022 | -52.72% |
| 2021 | -72.16% |
| 2020 | -61.71% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...